The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Thromboembolism Prophylaxis in Hospitalization

Systematic prevention of venous thromboembolism (VTE — deep venous thrombosis DVT and pulmonary embolism PE) in hospitalized medical and surgical patients through risk stratification, application of pharmacologic prophylaxis (low molecular weight heparin LMWH most commonly enoxaparin, unfractionated heparin UFH, fondaparinux, direct oral anticoagulants DOACs in selected populations), mechanical prophylaxis (intermittent pneumatic compression devices, graduated compression stockings, venous foot pumps), or combination therapy; based on validated risk assessment tools (Padua Prediction Score for medical patients, IMPROVE bleeding risk score, Caprini Risk Assessment Model for surgical patients), with prophylaxis duration ranging from hospital stay only to extended prophylaxis (typically 4-5 weeks for high-risk surgical patients including cancer surgery, hip and knee replacement); represents one of the most important hospital-acquired condition prevention strategies given that VTE is the most common preventable cause of in-hospital death and significant morbidity, with appropriate implementation reducing VTE incidence by 60-80 percent.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Thromboembolism Prophylaxis in Hospitalization?

Thromboembolism prophylaxis in hospitalization refers to the systematic application of preventive measures to reduce the risk of venous thromboembolism (VTE — deep venous thrombosis and pulmonary embolism) in hospitalized patients, who are at significantly increased risk due to combinations of immobilization, acute illness, surgery, medical conditions, and other thrombogenic factors. VTE is one of the most common preventable causes of in-hospital morbidity and mortality, with significant clinical and economic consequences. Appropriate prophylaxis can reduce VTE incidence by 60-80 percent in high-risk patients.

Epidemiology and clinical importance: 1) Without prophylaxis, hospitalized medical patients have 10-20 percent VTE risk and surgical patients 15-40 percent risk depending on procedure type; 2) Hospitalized patients represent 50-70 percent of all VTE cases overall (community plus hospital); 3) Pulmonary embolism is the most common preventable cause of in-hospital death, accounting for 5-10 percent of hospital deaths; 4) Post-thrombotic syndrome (chronic venous insufficiency, leg pain and swelling) develops in 20-50 percent of DVT survivors causing significant long-term morbidity; 5) Recurrent VTE risk lifelong (3-10 percent annually after first event); 6) Significant economic costs from acute treatment, long-term complications, recurrence; 7) Despite known benefit, prophylaxis is underutilized worldwide (40-60 percent of high-risk patients receive appropriate prophylaxis) representing major opportunity for quality improvement.

Risk assessment for VTE: 1) Medical patients — Padua Prediction Score (validated, recommended) including: active cancer 3 points, previous VTE 3 points, reduced mobility (≥3 days bed rest) 3 points, thrombophilic condition 3 points, recent trauma/surgery (within 1 month) 2 points, age ≥ 70 years 1 point, heart failure or respiratory failure 1 point, MI or ischemic stroke 1 point, acute infection or rheumatologic disorder 1 point, BMI ≥ 30 1 point, ongoing hormonal treatment 1 point; total ≥ 4 indicates high risk warranting prophylaxis; 2) Surgical patients — Caprini Risk Assessment Model with comprehensive multi-point scoring including age (1-5 points), surgery type (1-5 points), BMI 25-29 (1 point) ≥30 (2 points), inflammatory bowel disease (1 point), heart failure (1 point), severe lung disease (1 point), spinal cord injury (5 points), stroke (5 points), cancer (2 points), oral contraceptive (1 point), pregnancy postpartum (1 point), thrombophilia (3 points), VTE history (3 points), family history (3 points), prosthetic device (5 points); risk categories — low (0-1), moderate (2), high (3-4), very high (≥5); 3) Bleeding risk assessment with IMPROVE score for medical patients (active gastric/duodenal ulcer 4.5 points, bleeding within 3 months 4 points, platelets < 50,000 4 points, age ≥85 vs <40 reference, hepatic failure 2.5 points, severe renal failure 2.5 points, ICU admission 2.5 points, central venous catheter 2 points, rheumatic disease 2 points, current cancer 2 points, male sex 1 point, age 40-84 1.5 points); high risk (>10 percent bleeding, score ≥7) contraindicates pharmacologic prophylaxis preferring mechanical alone.

Pharmacologic prophylaxis options: 1) Low molecular weight heparin (LMWH) — preferred in most patients; advantages include fixed dosing without weight-based adjustment in standard renal function, predictable pharmacokinetics, less HIT risk than UFH, no monitoring typically needed; agents include: a) Enoxaparin (Lovenox) 40 mg subQ daily for medical and most surgical patients (some institutions 30 mg twice daily for high-risk orthopedic); reduce to 30 mg daily for severe renal impairment (CrCl < 30 mL/min); b) Dalteparin (Fragmin) 5,000 units subQ daily; c) Tinzaparin; d) Bemiparin; 2) Unfractionated heparin (UFH) — 5,000 units subQ every 8-12 hours; preferred in severe renal failure (CrCl < 30 mL/min when LMWH avoided), pregnancy, immediate need for reversal possibility; disadvantages include 1-3 percent HIT risk, requires aPTT monitoring at therapeutic doses (not prophylactic), more variable response; 3) Fondaparinux 2.5 mg subQ daily — synthetic factor Xa inhibitor; alternative in HIT history; less commonly used than LMWH; 4) Direct oral anticoagulants (DOACs) — apixaban (Eliquis) 2.5 mg twice daily for orthopedic prophylaxis 12-35 days, expanded use in medical inpatients with high VTE/low bleeding risk; rivaroxaban (Xarelto) 10 mg once daily for orthopedic prophylaxis 12-35 days; dabigatran (Pradaxa) 220 mg daily for orthopedic prophylaxis 30 days; some MAGELLAN, MARINER, ADOPT data on extended medical inpatient prophylaxis with apixaban, rivaroxaban, betrixaban; 5) Aspirin — limited evidence in some orthopedic situations, not first-line for medical inpatients; 6) Warfarin — not preferred for prophylaxis due to slow onset and need for monitoring.

Symptoms

Hospitalization with significant medical illness
Recent major surgery (especially abdominal, pelvic, orthopedic, cancer)
Hip or knee arthroplasty
Hip fracture surgery
Cancer surgery
Reduced mobility ≥ 3 days
ICU admission
Active cancer (especially solid tumor with chemotherapy)
Acute medical illness (heart failure, pneumonia, COPD exacerbation, MI, stroke)
Acute infection or sepsis
Trauma with multiple fractures or pelvic/femoral injury
Spinal cord injury with paralysis
Major neurosurgery
Personal history of VTE
Family history of VTE
Thrombophilia (Factor V Leiden, prothrombin gene mutation, antiphospholipid antibody syndrome, protein C/S/antithrombin deficiency)
Pregnancy or postpartum period (extended prophylaxis recommended)
Estrogen therapy or oral contraceptives
Tamoxifen or other selective estrogen receptor modulators
Inflammatory bowel disease
Severe lung disease
Heart failure
Obesity (BMI > 30)
Advanced age (> 65 years)
Indwelling central venous catheter
Prolonged immobilization (> 8 hour flights, prolonged bed rest)
Large surgical procedure with prolonged anesthesia

Risk Factors

Patient on antithrombotic therapy contraindication for prophylaxis (active bleeding)
Severe thrombocytopenia (platelets < 50,000)
Active gastrointestinal ulcer with bleeding
Recent intracranial hemorrhage (within 30 days)
Hemorrhagic stroke (within 30 days)
Recent neurosurgery (within 30 days)
Recent ophthalmologic surgery (within 14 days)
Active major bleeding requiring transfusion
Severe renal failure (CrCl < 15 mL/min for some agents)
Severe hepatic failure (Child-Pugh C)
Heparin-induced thrombocytopenia history (avoid UFH/LMWH, use fondaparinux or DOAC)
Spinal/epidural anesthesia or planned procedures within 12-24 hours of LMWH (timing critical for spinal hematoma prevention)
Bleeding diathesis (von Willebrand disease, hemophilia)
Severe uncontrolled hypertension
Concomitant antiplatelet therapy (aspirin plus clopidogrel)
Congenital or acquired bleeding disorders
Recent major trauma with bleeding risk
Patient refusal of pharmacologic prophylaxis
Poor compliance with subcutaneous injections
Cost considerations in resource-limited settings

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • All hospitalized patients should be assessed for VTE prophylaxis
  • Every patient admission requires VTE risk assessment
  • Surgical procedures requiring assessment
  • ICU admission requires assessment
  • Cancer patient hospitalization
  • Patients with personal/family history of VTE
  • Pregnant or postpartum hospitalization
  • Pre-procedural anticoagulation management
  • Post-discharge extended prophylaxis evaluation
  • Suspected DVT (leg pain, swelling, redness, warmth)
  • Suspected PE (sudden dyspnea, chest pain, hemoptysis, syncope)
  • Bleeding while on prophylaxis (need for management)
  • HIT suspicion (platelet count drop, new thrombosis)
  • Prophylaxis failure (VTE despite prophylaxis)
  • Drug-drug interactions affecting prophylaxis
  • Renal function changes affecting drug choice
  • Body weight changes affecting dose
  • Prolonged hospitalization decision-making

Treatment Methods

01
Risk assessment and prophylaxis decision: 1) Admission VTE risk assessment using validated tool (Padua for medical, Caprini for surgical) and bleeding risk assessment (IMPROVE bleeding score for medical, surgical-specific tools); 2) Documentation in medical record with reasoning; 3) Order set integration with electronic health record (computerized order sets significantly improve compliance); 4) Multidisciplinary review (pharmacist, nursing, physician); 5) Appropriate selection between pharmacologic, mechanical, or combination prophylaxis; 6) Re-assessment with clinical status changes throughout hospitalization; 7) Discharge planning including extended prophylaxis when indicated
02
Pharmacologic prophylaxis implementation: 1) Most commonly enoxaparin 40 mg subQ daily (medical, surgical); some institutions enoxaparin 30 mg twice daily (high-risk orthopedic surgery); 2) UFH 5,000 units subQ q 8-12 hours alternative (preferred in severe renal failure, pregnancy, immediate reversal need); 3) Fondaparinux 2.5 mg subQ daily for HIT history; 4) Apixaban 2.5 mg PO twice daily or rivaroxaban 10 mg PO daily as DOAC alternatives in selected populations; 5) Timing considerations — initiation 12-24 hours post-surgery to balance bleeding versus thrombosis risk (post-orthopedic surgery typically 12-24 hours); 6) Renal dose adjustments — enoxaparin reduce to 30 mg daily if CrCl < 30 mL/min; UFH preferred for severe renal impairment when reversal needed; 7) Hepatic considerations — caution with severe liver disease; 8) Drug interactions reviewed (azole antifungals, NSAIDs increased bleeding risk)
03
Mechanical prophylaxis methods: 1) Intermittent pneumatic compression (IPC) devices — most effective mechanical method; sequential or uniform compression, typically applied to calves or both calves and thighs; require continuous use; advantage in patients with bleeding risk contraindicating pharmacologic; 2) Graduated compression stockings (GCS) — pressure 18 mmHg ankle to 10 mmHg thigh; less effective alone but adjunctive value; appropriate fit critical (avoid in peripheral arterial disease, leg ulcers, severe edema); 3) Venous foot pumps — alternative for hip/knee surgery patients when calf-thigh sleeves not feasible; 4) Continuous use (typically 23 hours per day with breaks for hygiene); 5) Combined mechanical and pharmacologic in very high-risk patients (typically not in standard medical patients without bleeding risk); 6) Cost-effectiveness analysis supports routine use in appropriate patients; 7) Patient comfort and compliance considerations
04
Special populations: 1) Pregnancy — LMWH is preferred (does not cross placenta, no fetal effects); UFH alternative; warfarin contraindicated in first and third trimesters (teratogenic); DOACs not recommended due to limited data; doses guided by anti-Xa monitoring during pregnancy due to physiologic changes; postpartum prophylaxis 6 weeks for high-risk patients; 2) Cancer patients — increased VTE risk lifelong; cancer surgery requires extended prophylaxis 4 weeks; ambulatory cancer patients with chemotherapy may benefit from extended prophylaxis (apixaban, rivaroxaban) based on Khorana score; 3) Pediatric — limited evidence, individualized assessment; UFH or LMWH options; 4) Renal failure — UFH preferred in severe disease, LMWH dose-adjusted for moderate disease, DOACs require caution; 5) Hepatic failure — caution with all anticoagulants, often combined approach with mechanical; 6) Bariatric surgery — extended prophylaxis 7-10 days, increased dose may be needed for high BMI; 7) HIT history — fondaparinux, DOAC, or argatroban (in active HIT); avoid heparin products; 8) Spinal anesthesia/epidural — careful timing of LMWH around spinal/epidural placement and removal (12-24 hours hold); 9) Obese patients — weight-based dosing considerations, particularly BMI > 40 or weight > 120 kg
05
Duration of prophylaxis: 1) Medical patients — duration of acute medical illness and reduced mobility (typically 6-14 days); some evidence for extended prophylaxis 35-39 days post-discharge in high-risk medical patients; 2) Abdominal/pelvic surgery — 7-10 days; extended 4 weeks for cancer surgery; 3) Hip arthroplasty — 30-35 days; 4) Knee arthroplasty — 12-14 days minimum, often 30-35 days; 5) Hip fracture surgery — 30-35 days; 6) Cancer surgery — 4 weeks (extended); 7) Major trauma — until mobile and discharge; 8) Spinal cord injury — at minimum 12 weeks if no other contraindications, often longer; 9) Critical care — variable based on continued risk factors
06
Common complications and management: 1) Bleeding — minor bleeding manage conservatively, hold prophylaxis briefly, restart when stable; major bleeding requires reversal (protamine for UFH and partially LMWH, andexanet alfa for apixaban/rivaroxaban, idarucizumab for dabigatran, vitamin K for warfarin), supportive care including transfusion, identification of bleeding source; 2) Heparin-induced thrombocytopenia (HIT) — Type I (mild, transient, immediate) versus Type II (immune-mediated, paradoxical thrombosis); 4 T's score for clinical probability; if HIT suspected, discontinue heparin, initiate alternative anticoagulant (argatroban, fondaparinux, DOAC), avoid platelet transfusions; long-term avoidance of heparin products; 3) Spinal/epidural hematoma — extremely rare but devastating; risk increased with anticoagulants; careful timing of LMWH around procedures; immediate evaluation if neurologic deficit; 4) Drug-drug interactions — important to review (NSAIDs, antiplatelets, azole antifungals, cyclosporine, etc.); 5) Subcutaneous tissue reactions — rare; 6) Allergic reactions to LMWH or UFH — alternative agent; 7) Local injection site reactions
07
Quality improvement and protocols: 1) Standardized institutional protocols essential for consistent prophylaxis; 2) Computerized order sets with prompt for risk assessment and contraindication screening; 3) Clinical decision support; 4) Mandatory risk assessment on admission and at clinical status changes; 5) Multidisciplinary team approach; 6) Education for nursing, pharmacy, and physicians; 7) Regular audit and feedback on prophylaxis rates; 8) National quality measures track VTE prophylaxis rates; 9) Hospital-acquired condition tracking and reporting; 10) The Joint Commission and CMS specify VTE prevention measures
08
Special situations and considerations: 1) Patient transitions of care — communicate prophylaxis status during shift handoffs, transfers, discharge; 2) Surgery during prophylaxis — hold timing pre-op, restart post-op based on hemostasis and bleeding risk; 3) Procedures (LP, central line, biopsy) — appropriate hold of pharmacologic prophylaxis; 4) Bleeding while on prophylaxis — assessment and management with consideration of risk-benefit, possible mechanical alternative; 5) Newly diagnosed bleeding disorder — anticoagulation reconsidered; 6) Worsening renal function — dose adjustment or change of agent; 7) Drug shortage — alternative agent selection; 8) Patient education on signs of DVT and PE for early recognition; 9) Post-discharge education for patients on extended prophylaxis (proper administration, recognizing complications); 10) Telehealth and home health considerations for ongoing prophylaxis monitoring

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.